This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.
OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays
by Zacks Equity Research
Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.
Shockwave Medical (SWAV) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and expansion in gross margin.
Allscripts' (MDRX) Stock Falls 8.8% Post Q1 Earnings Miss
by Zacks Equity Research
Allscripts' (MDRX) robust Q1 results demonstrate strength in both segments.
Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat
by Zacks Equity Research
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.
DENTSPLY SIRONA (XRAY) Reports Weak Q1 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary first-quarter 2022 results reflect weakness in segments.
Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.
AMN Healthcare (AMN) Q1 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q1 results demonstrate its segmental strength.
McKesson (MCK) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2022 results benefit from segmental growth.
Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.
Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.
DaVita (DVA) Misses on Q1 Earnings, Reiterates FY22 EPS View
by Zacks Equity Research
Despite strength in dialysis patient service revenues, DaVita (DVA) records an overall soft Q1 performance.
CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Quidel (QDEL) Q1 Earnings, Revenues Surpass Estimates, Up Y/Y
by Zacks Equity Research
Quidel's (QDEL) robust performance across two of its product categories drives its first-quarter 2022 top line.
CONMED's (CNMD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) first-quarter earnings reflect strong segmental performance.
PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.
LHC Group (LHCG) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group's (LHCG) first-quarter results benefit from organic growth in both home health as well as hospice admissions.
Cardinal Health (CAH) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from a solid performance in the Pharmaceutical segment.
BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Masimo's (MASI) Q1 Earnings Surpass Estimates, FY22 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments drive its Q1 sales.
Cerner (CERN) Q1 Earnings in Line, Revenues Lag Estimates
by Zacks Equity Research
Cerner's (CERN) first-quarter results benefit from gains across four of its business units.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from a solid performance at Discover & Analytics Solutions business.